We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The Society for Immunotherapy of Cancer (SITC) Combination Immunotherapies Task Force has convened to:
The Combination Immunotherapies Task Force focus is upon the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer. Standardization of assays, assay validation, and appropriate potency assays were the subjects of one subcommittee while the other assessed the clinical utility of promising novel technologies and made recommendations on how to incorporate these into the clinical arena.
Patrick Ott, MD, PhD
Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*]
Stanford Cancer Institute
F. Stephen Hodi, MD
Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS
Rutgers Cancer Institute of New Jersey
Jon M. Wigginton, MD
Jedd D. Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)
Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
Hello SITC community! I will appreciate any insights going forward for AML patients who have progressed after receiving allogeneic BMT and currently enrolled for treatment with Gilteritinib. Will such patients benefit from currently approved immunotherapies ...
This message was posted by a user wishing to remain anonymous Given that each cytokine degrades at different points in the media...while setting up a multiplex in vitro cytokine profiling assay, (with PBMCs post treatment) what is the best time point ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
Animal models have shown intestinal microbiota are crucial for therapeutic efficacy for CTLA4 blockade ( has decreased tumor size) and anti-PD1 psychotherapies.That the microbiome may be a target that can be modulated to enhance treatment responses. Theoretically, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com